share_log

TD Cowen Downgrades Keros Therapeutics to Hold

Benzinga ·  Dec 13 02:07

TD Cowen analyst Tyler Van Buren downgrades Keros Therapeutics (NASDAQ:KROS) from Buy to Hold.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment